Key result
Gene therapy emerges as a promising mechanism-based treatment targeting the molecular drivers of AF.
Why the study?
Current treatments for atrial fibrillation are suboptimal because they do not target the underlying molecular mechanisms, whereas gene therapy is emerging as a promising mechanism-based approach.
Does gene therapy provide a mechanism-based treatment for atrial fibrillation?
Does gene therapy provide a mechanism-based treatment for atrial fibrillation?
Gene therapy is emerging as a promising mechanism-based approach for treating atrial fibrillation, addressing the limitations of current suboptimal treatments.
Gene therapy for AF remains experimental; leaves open whether mechanism-based approaches will prove effective in trials.
Atrial fibrillation (AF) is the most common heart rhythm disorder in adults and a major cause of stroke. Unfortunately, current treatments for AF are suboptimal as they are not targeting the molecular mechanisms underlying AF. In this regard, gene therapy is emerging as a promising approach for mechanism-based treatment of AF. In this review, we summarize recent advances and challenges in gene therapy for this important cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2021) conducted a review in Atrial fibrillation. Gene therapy was evaluated. Gene therapy is emerging as a promising approach for the mechanism-based treatment of atrial fibrillation, addressing the molecular mechanisms underlying the disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: